Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2017 3
2019 4
2020 9
2021 13
2022 17
2023 23
2024 22
2025 27
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé RBM, Van den Bosch FE, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen FA, Géher P, Gensler L, Hermann J, de Hooge M, Husakova M, Kiltz U, López-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D. Ramiro S, et al. Ann Rheum Dis. 2023 Jan;82(1):19-34. doi: 10.1136/ard-2022-223296. Epub 2022 Oct 21. Ann Rheum Dis. 2023. PMID: 36270658 Free article.
Recommendation 9 describes the indication of biological DMARDs (bDMARDs, that is, tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i)) and targeted synthetic DMARDs (tsDMARDs, ie, Janus kinase inhibitors) for patients wh …
Recommendation 9 describes the indication of biological DMARDs (bDMARDs, that is, tumour necrosis factor inhibitors (TNFi), interleuk …
Axial Spondyloarthritis: A Review.
Bittar M, Deodhar A. Bittar M, et al. JAMA. 2025 Feb 4;333(5):408-420. doi: 10.1001/jama.2024.20917. JAMA. 2025. PMID: 39630439 Review.
Approximately 75% of patients require biologic drugs (tumor necrosis factor inhibitors [anti-TNF agents], interleukin 17 inhibitors [anti-IL-17 agents]) or targeted synthetic disease-modifying antirheumatic agents (Janus kinase [JAK] inhibito …
Approximately 75% of patients require biologic drugs (tumor necrosis factor inhibitors [anti-TNF agents], interleukin 17 inhibitor …
Axial spondyloarthritis.
Navarro-Compán V, Sepriano A, Capelusnik D, Baraliakos X. Navarro-Compán V, et al. Lancet. 2025 Jan 11;405(10473):159-172. doi: 10.1016/S0140-6736(24)02263-3. Lancet. 2025. PMID: 39798984 Review.
Although chronic back pain and spinal stiffness are typical initial symptoms, peripheral (ie, enthesitis, arthritis, and dactylitis) and extra-musculoskeletal (ie, uveitis, inflammatory bowel disease, and psoriasis) manifestations are also common. Timely and accurate diagn …
Although chronic back pain and spinal stiffness are typical initial symptoms, peripheral (ie, enthesitis, arthritis, and dactylitis) and ext …
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Cañete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS. Gossec L, et al. Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531. Ann Rheum Dis. 2024. PMID: 38499325 Free PMC article.
Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, w …
Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, o …
JAK-STAT inhibitors in noninfectious uveitis - A review.
Pyare R, Shaikh N, Sen A, Kene R, Bagri N, Janarthanan M, Chawla R, Ramanan AV, Dutta Majumder P. Pyare R, et al. Indian J Ophthalmol. 2025 Jun 1;73(6):807-815. doi: 10.4103/IJO.IJO_61_25. Epub 2025 May 28. Indian J Ophthalmol. 2025. PMID: 40434456 Free PMC article. Review.
One such example is the use of TNF-alpha inhibitors, such as adalimumab and infliximab. These biologics target specific inflammatory cytokines, unlike the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. …
One such example is the use of TNF-alpha inhibitors, such as adalimumab and infliximab. These biologics target specific inflammatory …
JAK-STAT signaling pathway in non-infectious uveitis.
Su Y, Tao T, Liu X, Su W. Su Y, et al. Biochem Pharmacol. 2022 Oct;204:115236. doi: 10.1016/j.bcp.2022.115236. Epub 2022 Aug 27. Biochem Pharmacol. 2022. PMID: 36041544 Review.
Cytokine receptors transmit signals by activating Janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins. ...Moreover, available evidence for the safety and efficacy of JAK inhibitors for refractory uveitis …
Cytokine receptors transmit signals by activating Janus kinase (JAK) and signal transducer and activator of transcripti …
Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis.
Dominguez D, Vaclaw S, McClard CK, Jeffries MA, Noori J. Dominguez D, et al. J Ophthalmic Vis Res. 2025 May 5;20:10.18502/jovr.v20.14952. doi: 10.18502/jovr.v20.14952. eCollection 2025. J Ophthalmic Vis Res. 2025. PMID: 40689111 Free PMC article.
PURPOSE: Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic uveitis. Janus kinase (JAK) inhibitors, one of the newest biologics, have shown successful outcomes in treat …
PURPOSE: Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic …
Uveitis and spondyloarthropathies.
Sharma SM, Jackson D. Sharma SM, et al. Best Pract Res Clin Rheumatol. 2017 Dec;31(6):846-862. doi: 10.1016/j.berh.2018.08.002. Epub 2018 Oct 25. Best Pract Res Clin Rheumatol. 2017. PMID: 30509444 Review.
The majority of cases of uveitis in SpA are attributed to acute anterior uveitis but a minority of uveitis cases occur in the posterior segment of the eye. ...Other targets in spondyloarthropathy include cytokines within the IL23/IL17 axis, of which the IL17A …
The majority of cases of uveitis in SpA are attributed to acute anterior uveitis but a minority of uveitis cases occur …
Biotherapies in Uveitis.
Leclercq M, Desbois AC, Domont F, Maalouf G, Touhami S, Cacoub P, Bodaghi B, Saadoun D. Leclercq M, et al. J Clin Med. 2020 Nov 8;9(11):3599. doi: 10.3390/jcm9113599. J Clin Med. 2020. PMID: 33171664 Free PMC article. Review.
Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. ...However, for intermediate, posterior and pan-uveitis, notably when both eyes are involved, systemic treatment is usually warranted. ...
Non-infectious uveitis (NIU) represents one of the leading causes of blindness in developed countries. ...However, for intermediate, …
117 results